sure enough, with biogen there was a cluster of timing cycles due from march 16 through march 18.o it is no coincidence the lows were smack in the middle on the 17th. just like with the ibb this is a nice double bottom pattern. most people think the stock will go lower. she believes it can rally. she said she would be a buyer on pull backs. using the same logic that identified where it was likely to bottom she says yishl targets of 283 and maybe 294. 10% gain at these levels. if bioge n, all bets are off. i have to admit the trust is tempted. but these charts make the trust want to buy more. i want to wait and see if the line holds. it's important. how about regeneron we followed since it was a $5 stock. there are fabulous stocks thanks to the macular degeneration drug. since last summer the stock was put through the meat grinder along with the rest of the group. take a gander at the daily chart. okay? like the others, regeneron made a double bottom which keeps coming up in february and march. it looks to be breaking up to the upside. last week it took out a prior high at 384. the

we have a ton of earning reports coming this morning, among them biogen, alphabet formerly known as google the big ones to watch after the bell today. meanwhile, companies across the u.s. are losing a staggering $10 billion a year from employee opiate addiction. the painkiller abuse is calling huge amounts of absenteeism and the new report shows one-third funded by employee health care plans are being abused. >>> volkswagon set something the case of the diesel emission. they'll pay $1 billion to compensate owners, $5,000 each. back over to you. >>> thank you much. just ahead, a baseball player who throws 105 miles per hour, and he is not a pitcher. greece was buzzing, the olympics has begun. has begun. -without the need for fillers. your concert tee might show your age...your skin never will. olay regenerist. olay. ageless. and try the micro-sculpting cream you love... ...now with lightweight spf 30 i'vand i'm doing just fine. allergies. claritin provides 24-hour relief of symptoms that can be triggered by over 200 allergens. yeah, over 200 allergens! with claritin my allergies don't come

biogen, general motors, verizon, alphabet formerly known as google are the big ones to watch after the bell today. wednesday the dow climbing 42 points to 18,096. volkswagen reached a deal with u.s. authorities to settle the case over its emissions test. it is set to offer 6,000 cars and will pay $1 billion to compensate owners. that's about $5,000 each. >> apple is delaying its earnings report by one day to tuesday april 26. the company says this move is to accommodate a memorial service for bill campbell who was one of the most influential players in the tech industry. known as coach, he played a significant role advising apple and google. back to you. >> landon dowdy, thank you very much. >>> facebook coo cheryl sandberg is fighting childhood hunger in the bay area. >> people don't realize there is so much hunger in the bay area. one in three children who lives in our area faces hunger, which means they do not know where all their meals are coming from. >> quite a contrast with all the money in silicon valley. in an exclusive interview, sandberg says she is working with the second h

. >> of the well-known bio techs all down year to date, biogen, virtex, gilead, any? >> biogen. we were talking after this whole deal fell apart, there's two options out there for allergen. a lot of people were discussing this. do you buy back your own stock? you're going to get $40 billion first half of this year. in your pocket to do something with. either you buy your own stock or you buy your own stock and maybe go out and buy somebody else. that was part of why we saw so much movement yesterday, scott. with some of these bio tech names that were flying to the upside. when you take a look, why were they moving quite as fast? it wasn't about so much news stories. i think the news story there was allergen and the money they were going to have along with pfizer. >> buyer or seller? >> i'm a buyer. i think when josh and i both talked about the ibb, that's the one i follow and when we saw that basically hit 240, that level and just bounce like a rocket off of it. it hit that for a hot second and moved up and moved higher. and it's a consolidation. very possibly. it just goes high

it's like perspective here, losing the entire value say of an american express or a biogen or it's worth two valero energies or worth three hormels. a slew of analysts took down their average price targets. they forecast a 34% gain for apple shares. now it's about whether the stock has caught the attention of some of those value-geared traders. back over to you, mem lisa, i mean, simon. just kidding. i knew it was you, simon. >> pretty much have a good weekend. let's send it over, how do the charts look here? >> if we know an uptrend is defined, clearly an uptrend for quite some time, higher high, higher low, a downtrend is the opposite. that's what we have been in for the better part of a year. higher high is lower lows. you can draw your lines as charters or tech fixes are inclined to do. here's another way, a triple top. another way, we come back to the new downtrend. we're failing. here's another way, can you call it a head and shoulders top t. reality is we are hovering ominously at these lows. ultimately to my high, anyway, we have low tore go, perspectively down here filling this

biogen, general motor, verizon, under armour, plus alpha bet formerly known as google and visa are the big ones to watch after the beg. >>> companies across the u.s. are losing a staggering $10 billion a year from employee opiate addiction. it's causing huge amounts of absenteeism, and lost productivity and the one-third of the pain killer prescriptions funded by health care plans are being abused? >>> and volkswagen reached a deal to settle the case over its cheating of diesel emissions test. vw is set to offer back nearly 600,000 u.s. diesel cars. the company will pay $1 billion to compensate owners about $5,000 each. betty, back over to you. >>> up next, a 24-hour waiting period may be wanted for anyone who wants viagra for sex. >>> and merriam-webster is adding 2,000 new words and phrases to the dictionary. among them is fomo, fear of missing out. and hella and revenge porn, and nomophobia, that is the fear of being without working access to the cell phone. oh, no. we'll be right back. ♪ ♪ you live life your way. we can help you retire your way, too. financial guidance while you're

it's like losing the entire value of, say, an american express, or a biogen. or it's worth two veleros. even those reduced targets on average forecast a 34% gain for apple shares. now, it's about whether the stock has caught the attention of some of those value geared traders. back over to you, melissa -- i mean, simon. just kidding. i knew it was you, simon. >> thank you very much, dom, have a good weekend. carter, how do the charts look here? >> let's look at it to the. if we know an uptrend is defined and clearly an uptrend for quite some time, higher highs and lower lows, decline has been the opposite. lower highs, lower lows. you also can draw your lines any way you want as charters or technicians are inclined to do. here's one way, a triple top. here's another way, we've come right back to the new down trend. and we're failing. here's another way. call it head and shoulders top. but the reality is, we're hovering ominously right here at these lows. ultimately, to my eye anyway, we have lower to go. potentially down filling this gap. here's the long-term

imagine as you can see, things are evolving even as we speak, biogen had earnings beating estimates. issues willng labor put pressure on the second quarter earnings. mark: the stoxx 600 was trading lower head of the ecb announcement. it is still lower. hopefully, i'll be able to give some of the sections for you. we do not they said need to do more. he said let's give it time to see if they will do more. they've moved into 17 and 18 and trying to figure out how lending travels were approved. it is still early. this is a great charge think about how the euro has fared. the euro was at 116. when we begin in march of last inr, they went from december 106. we are at 113. we were down about 1/10 of 1% earlier. guests about the euro movement. they are focusing on the credit channel. today,, they need $10 billion to resolve civil claims by the u.s. government and lawsuits over american car owners. there's according to a person saying that was a big fall last year. then, before they had the market capital at 76.7. to 47 in billion. they are coin back most of the market cap since the commissi

as biogenic all why are biotech stocks rallying? because of what is not happening with pfizer and allergan. new in version rules are coming from the department of treasury. that means there's cash on the table for other perspective mergers. i will send it back to you but a big day on the nasdaq. for every one stock down, to stocks are up. emily: coming up, just in time for tax income a multibillion dollar market place to buy tax credits. we will bring you the details. ♪ getting a boost -- the wireless company will sell and lease back network equipment in a move that would ring in $2 billion in funding. the new influx of money will be used to pay down debt coming due. sprint has a total of $35 billion in debt. time to pay the u.s. taxman is just around the corner and a new multibillion marketplaces allowing investors to get in on the action with major hollywood studios. several studios are looking to sell and trade their unused state tax credits. is estimated to be worth $100 billion had online incentive exchange launched the first s

contrast to the s&p in the dow and the differences by a tech which is trading sharply which isiven by biogen for the day. they beat first-quarter earnings by 7%. big number so there was a slight revenue miss but investors are looking past that. eric schmidt says the company is treading water on the top line but made up or it on the bottom line. can they keep that cost-cutting effort going and will they manage to make some sort of attractively priced acquisition considering so many biotech companies are trading cheap? betty: you have been hearing a lot about rv today. can you tell us what's going on with mattel. abigail: it seems barbie is a little less popular than she is to be. the firstled in quarter causing mattel to post a wider than expected first loss. -- first-quarter loss. we have a lot of analysts who are positive saying this was driven by currency headwinds and one analyst who is bullish is linda weiser was recommending to aggressively buy this stock. months, we see the weakness is wiped out the near-term support. the 100 day moving average suggesting that some of the medium-term b

a ton of earnings coming our way including biogen, general motors, under armour and alphabet known as google. 18,096. nasdaq up seven. >> what is a news update without a tesla update? elon musk says the company has reservations for 400,000 of the new model 3. you can say you have a lot of reservations about these cars, that is a good thing. >> is there a cut-off at some point? production is going to be really difficult. >> that is an excellent question. i'm going to speculate here. if there were a cut-off, it should have come a long time ago. now there's something like eight years of production out. they should have cut this off. >> they could have the new technology for a new car by the time your first car arrives. >>> thank you. check this out. a secret tunnel. between mexico and the u.s., eight football fields long complete with a rail system,2 ventilation, lights and an elevator. smugglers use it to transport drugs to san diego. two tons of cocaine, seven tons of marijuana seized. authorities say the drugs have a total street value $22 million. six people have been arrested. >>>

how we talk about the biotech, because there is biotech with the big name of the celgenes and the biogensand the tech like this half a billion market cap, and the volatility that jon is talking about right now, and these are different. you are not talking about the earnings, but talking about getting a stock that you are looking at, and phase three, and you are trying to get a stock into the marketplace or excuse me, a drug into the marketplace, and that is a difference. people have the understand the difference of some of the company, and yes, everybody has face street in the pipeline, but it is the companies that don't have drugs on the market or very little in terms of earnings like this company or those who have all kinds of different drugs, but trying to develop more, and that the huge difference between. >> to me, the bigger story or the lesson especially with the biotech and pharma is not to vote with the harriet, and when you see the advisory panel meeting, it was supposed to be 10 or 11 hours and filled with people who have family members suffering from the disease and it is toug

. >> and biogen with bert than expected earnings? steve weiss? >> well, part of it is if there was a fear that they could have had it worse, but it is a good quarter and positive quarter, but mixed numbers in terms of the sales of the ms drugs for example. >> and pete, why is united airlines getting smoked today? >> guidance. it is all about the guidance and when you look at the quarter, it is decent and nothing great, and it should be great, because over at southwest they put up the unbelievable numbers, and they have been the lagger, and we have talked about them being the lagger, and i thought that they would catch up quicker than they have, scott, and the guidance is going to be taking longer, and the new board and a lot of it are steps in the right direction, and the stock is way too cheap, but it is not meaning that it is too lower, and i am in the calls on the zero upside, and that is unfortunate for me, but ape not giving up on it. i believe it is going high e >> and rich, american, press? >> no. they beat by ten cents a share, but we bel

biogen zooming, nothing is too big. allergen is going to get $40 billion. even gilead is ramping, why not? like so many other drug companies, gill i can't tell stock are cheap. the fib and a half chi queen is 4 for 4 and because she's 4 for 4, the whole index, the big etf names, get taking up. now, none of this will be possible if valeant weren't getting killed today like usual. isn't that what usually happens? this stock has been a one-man bear market casting a pal over the entire group because the political program and regulatory scrutiny it brought to the industry. brent saunders took the idea of buying valeant off the table. even down here. but he didn't dismiss the idea of snapping up one of its divisions like the one he used to run, bausch & lomb. that plus a buckup conference call by the cheerleader in chief with the gigantic stake in the company shackle it had bear with some rah rah, worthy more of villanova than valeant. stocks stampeded higher and then it rallied hard again after the bell when the possibility of a debt deal may be in hand. vrx up

. >> i'm going with biogen.k about growth pharma, that's why he's looking at this particular name. the ms franchise and the fact that they are in the hemophilia, huge growth there as well, look the at the ref niece and earnings growth, the real key, they are very bottom. alzheimer's. they have a drug in late stage for alzheimer's, could be very huge. >> work on your penmanship. brian kelly, who should allergen buy? >> boston scientific, bsx, growth area, demographics support this that the medical surgical area. that's going to be a growth driver and look at the stock. it's been on an absolute tear and a relatively small bite compared to the others. >> best mate for allergen? >> interesting. >> here's way. they will be selling their again rings business to tiva and they will get $30 billion in cash. this is a company that has over $35 billion in debt. i think they should buying back their stock which would be creative in paying down debt. think of what just happened to valeant they accumulated a lot of debt over

if you compare biogen and amgen, the valuation should be higher. canceled allergan could take out another buyer. >> those names aren't getting too much of a bid in today's session. netflix is getting more bullish raising estimates into the quarter, kicking up $130 price target. they are expecting an inline quarter stronger guidance. they also point out international net ads and average revenue per using and contribution margin are more important met ricks and u.s. ad numbers are the ones behind the soft volatility. >> if you're that bullish, why not raise the price target. >> i like -- i really like it. >> starts coverage with a buy rating and notice this could shine by 2018, analysts said wendy's made substantial progress into the company and they sout off assets and you have a visible path through higher earnings and base case price of about $13. we'll call that their target. 18% higher -- >> gaining traction on the four for $4 menu versus mcdonald's and burger king's 2 for $5 menus. you couldn't make this up. >>> next up, in particular, 19 bucks

biogen's quarterly earnings beating expectations this morning thanks to its multiple sclerosis drug.s will likely help margins going forward. that stock up about 4%. other standouts include endo international, mallimallinckrod illumina and alexion farma. >> let's bring in john kernen. john, going into this quarter there were a lot of worries about whether under armour was losing market share in apparel. did the growth quiet concerns? >> the drivers of growth are shifting to international and footwear. clearly apparel in the u.s. whole sale channels probably slowing a little bit off an incredibly high base. we don't think they're losing growth drivers but they're shifting to other regions. >> would you agree, were you impressed by the different metrics? double digit sales growth across the board. >> i agree. growth metrics are changing where footwear and international are really starting to take over. footwear continue about 12% of the growth going forward and international about 10%. you really don't need 20% growth going forward, mid teens would do it. >> i wonder, john, if inventor

some movers within it biogen is up by 5%, regen ron, amgen. >>> harley-davidson trading lower at theirst quarter sales forecast was cut, siting after a stable start to the year. harley-davidson expected to report its earnings on the 19th. meantime share of cree are also following. you heard that story late yesterday, the l.e.d. maker preannounced quarterly results which were rely below the previous guidance and strief evidences, plaming product delays and lower commercial orders at its -- and here's something you don't see, an airline union in opposition of activists. >> this is are pilots for united airlines. altimeter is along with parr capital, a couple hedge funds trying to wage a proxy battle. the pilots were many in support of the ceo, a return to work last month. he's focused -- and overall improving the performance. the pilots say they don't need the distraction of a proxy battle to interrupt what mu i don't see is doing. >> let oscar munos do his job so we can give a better customer service. >> we truly don't know exactly what the groups have in mind. they have yet to state

amgen talked about the fact that they're looking at things, biogen just last week said they're lookingt a lot of assets. so the point is that bigger companies are saying they're looking at these assets. i it this bid spread is coming together. >> michael yee and les from esquared, good concrete ideas. we appreciate it. >> all right. >> thank you. >> meanwhile, more on the other big deals today in just a moment. first, some news in the bond market. seven year notes up for auction. how is it going, rick? >> i'll tell you, you put two central banks behind you, three including the ecb, you push yields down. you have everybody jump in long yesterday after the fed statement. you talk about the perfect landscape. this was an a. i almost gave it an a plus. this auction, they were just dying for these seven years. let's go through it. final of will 88 billion in supply today. 1.634. looked to me like 1.645. this was strong. bid to cover, 2.65. way above the 2.47 auction average and the best since february of '14. 65.5 at indirects. if you take out the three that we added in january at 69.4, thi

. >>> next up, biogen, raymond james is sticking about it strok buy rating.posted eps that beat revenue in line. that happened last night. higher sales of the drug lowered expenses driving that quarter. the bar is exceedingly low and he's excited about the pipeline. >> the price target is $384. so they see another $100 a share. >> because the bar is really low. biotech is really under fire. >> it has been. finally, under the radar name is called gas log. it has the best stock ticker ever, glog. this is a monday owe he could based company. jeffries upgrading it to a buy from a hold. the shipping smashgt about to get better because prices are stabilizing. gas log and another company in the upgrade are valued at a discount to net asset value. 16 analysts cover glog with a price target of $15.10. there you go. and the stock is up 6.5%. >> all right, we have a tech wreck. earnings from ago fa bet and microsoft weighing on the sector. the stock are down 6%. how do you play this group right now? we're trading big cap tech. that's next on "power." that's a lot of dis

the other one is a biological, injectable from the company biogen. they really invig rated -- invigorated the community last year. even though it was a small trial about 150 people, every one of the people had amyloid deposits in their brain based on a pet scan and after one year, those on the active treatment showed a slower decline based -- as compared to placebo. not only on their cognitive assessment scores but also based on the pet scan. believe it of not, that was the first time a trial has been done in this way where you knew you were treating people with amyloid deposits in the brain because we now have the tools to do it. and that has really excited the whole field because again, we're getting these diagnostic tools to help guide the clinical trials. but as i said, we had over 5 million americans with alzheimer's disease today and a prevention strategy is not doing to help them. we need something to help them with the symptoms so we have people who are working in that area too. so two examples, the rvt 101 compound. this is another symptomat